Novo Nordisk has signed off on a $285 million biobucks deal with fellow Denmark-based company Ascendis Pharma to help the Wegovy manufacturer develop a once-monthly GLP-1 receptor agonist.
Children and young people should not be put in the position to decide whether they can take powerful gender transition drugs, a former transgender patient has said. Keira Bell is backing legal action ...
Trump and his campaign have been vague about plans on health care policies, though current and former Trump aides have published blueprints that go well beyond reversing programs in force under the ...
ACTH is biologically similar to the MSH hormone, which stimulates the production of melanin ... The only available treatment is radioisotope therapy, which uses a radioactive drug that seeks out and ...